Skip to main content
SpringerLink
Log in

Recent Advances in Hematopoietic Stem Cell Transplantation and Perspectives of RNAi Applications

  • Protocol
  • First Online:
RNA Therapeutics

Part of the book series: Methods in Molecular Biology ((MIMB,volume 629))

  • 4711 Accesses

Abstract

In adults, the bone marrow compartment contains hematopoietic stem cells (HSCs) which can differentiate into progenitors with more restricted lineage potential and generate all cellular elements of the blood. HSCs for stem cell transplantation can be obtained by bone marrow collection, mobilization into peripheral blood followed by apheresis, or use of stem cells from cord blood. Currently, hematopoietic stem cell transplantation (SCT) is used to treat patients with various hematological diseases. Although substantial progress has been made, a number of challenges can limit the efficacy of HSC transplantation, including the occurrence of graft-versus-host disease (GvHD) in allogeneic stem cell transplantation (ASCT), the susceptibility of patients to opportunistic infections and relapse of malignancies after SCT. Recent studies indicate that small interfering RNAs (siRNAs) can specifically and efficiently interfere with the expression of oncogenic genes. Therefore, the possibility of interfering with the expression of these proteins in hematopoietic cells may offer a new option to correct cell differentiation and function. In addition to the generation of T cells restricted by nonself MHC as reviewed by Stauss and colleagues in 1999, the modulation of NK cell receptor expression and T-cell activation is a new strategy that could limit GvHD. This chapter reviews the recent advances in ASCT and discusses the potential application of RNAi in hematopoietic cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Civin, C.I., Strauss, L.C., Brovall, C., Fackler, M.J., Schwartz, J.F., and Shaper, J.H. (1984) Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol, 133, 157–165.

    PubMed  CAS  Google Scholar 

  2. Egeland, T., Tjonnfjord, G., Steen, R., Gaudernack, G., and Thorsby, E. (1993) Positive selection of bone marrow-derived CD34 positive cells for possible stem cell transplantation. Transplant Proc, 25, 1261–1263.

    PubMed  CAS  Google Scholar 

  3. Gratwohl, A., Baldomero, H., Schwendener, A., Rocha, V., Apperley, J., Frauendorfer, K., and Niederwieser, D. (2009) The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant, 43, 275–291.

    Article  PubMed  CAS  Google Scholar 

  4. Uzunel, M., Remberger, M., Sairafi, D., Hassan, Z., Mattsson, J., Omazic, B., Barkholt, L., and Ringden, O. (2006) Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation, 82, 913–919.

    Article  PubMed  Google Scholar 

  5. Remberger, M., Mattsson, J., Hausenberger, D., Schaffer, M., Svahn, B.M., and Ringden, O. (2008) Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. Eur J Haematol, 80, 419–428.

    Article  PubMed  CAS  Google Scholar 

  6. Heldal, D., Brinch, L., Tjonnfjord, G., Solheim, B.G., Egeland, T., Albrechtsen, D., Aamodt, G., and Evensen, S.A. (2003) Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study. Bone Marrow Transplant, 32, 257–264.

    Article  PubMed  CAS  Google Scholar 

  7. Ballen, K.K., Spitzer, T.R., Yeap, B.Y., McAfee, S., Dey, B.R., Attar, E., Haspel, R., Kao, G., Liney, D., Alyea, E., Lee, S., Cutler, C., Ho, V., Soiffer, R., and Antin, J.H. (2007) Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant, 13, 82–89.

    Article  PubMed  CAS  Google Scholar 

  8. Ballen, K.K. (2005) New trends in umbilical cord blood transplantation. Blood, 105, 3786–3792.

    Article  PubMed  CAS  Google Scholar 

  9. Barker, J.N., Weisdorf, D.J., DeFor, T.E., Blazar, B.R., McGlave, P.B., Miller, J.S., Verfaillie, C.M., and Wagner, J.E. (2005) Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood, 105, 1343–1347.

    Article  PubMed  CAS  Google Scholar 

  10. Tomizawa, D., Aoki, Y., Nagasawa, M., Morio, T., Kajiwara, M., Sekine, T., Shimizu, N., Kato, M., Yachie, A., and Mizutani, S. (2005) Novel adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation in Omenn syndrome. Eur J Haematol, 75, 441–444.

    Article  PubMed  Google Scholar 

  11. Dreger, P., Corradini, P., Kimby, E., Michallet, M., Milligan, D., Schetelig, J., Wiktor-Jedrzejczak, W., Niederwieser, D., Hallek, M., and Montserrat, E. (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia, 21, 12–17.

    Article  PubMed  CAS  Google Scholar 

  12. Sorror, M.L., Storer, B.E., Sandmaier, B.M., Maris, M., Shizuru, J., Maziarz, R., Agura, E., Chauncey, T.R., Pulsipher, M.A., McSweeney, P.A., Wade, J.C., Bruno, B., Langston, A., Radich, J., Niederwieser, D., Blume, K.G., Storb, R., and Maloney, D.G. (2008) Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol, 26, 4912–4920.

    Article  PubMed  Google Scholar 

  13. Dreger, P., Brand, R., Hansz, J., Milligan, D., Corradini, P., Finke, J., Deliliers, G.L., Martino, R., Russell, N., Van Biezen, A., Michallet, M., and Niederwieser, D. (2003) Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia, 17, 841–848.

    Article  PubMed  CAS  Google Scholar 

  14. Khouri, I.F., Saliba, R.M., Giralt, S.A., Lee, M.S., Okoroji, G.J., Hagemeister, F.B., Korbling, M., Younes, A., Ippoliti, C., Gajewski, J.L., McLaughlin, P., Anderlini, P., Donato, M.L., Cabanillas, F.F., and Champlin, R.E. (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood, 98, 3595–3599.

    Article  PubMed  CAS  Google Scholar 

  15. Vigouroux, S., Michallet, M., Porcher, R., Attal, M., Ades, L., Bernard, M., Blaise, D., Tabrizi, R., Garban, F., Cassuto, J.P., Chevalier, P., Facon, T., Ifrah, N., Renaud, M., Tilly, H., Vernant, J.P., Kuentz, M., Bourhis, J.H., Bordigoni, P., Deconinck, E., Lioure, B., Socie, G., and Milpied, N. (2007) Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica, 92, 627–634.

    Article  PubMed  Google Scholar 

  16. Rezvani, A.R., Storer, B., Maris, M., Sorror, M.L., Agura, E., Maziarz, R.T., Wade, J.C., Chauncey, T., Forman, S.J., Lange, T., Shizuru, J., Langston, A., Pulsipher, M.A., Sandmaier, B.M., Storb, R., and Maloney, D.G. (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphoma. J Clin Oncol, 26, 211–217.

    Article  PubMed  Google Scholar 

  17. Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., de Elvira, C.R., Taghipour, G., and Schmitz, N. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood, 100, 4310–4316.

    Article  PubMed  CAS  Google Scholar 

  18. Niscola, P., Romani, C., Cupelli, L., Scaramucci, L., Tendas, A., Dentamaro, T., Amadori, S., and de Fabritiis, P. (2007) Mucositis in patients with hematologic malignancies: an overview. Haematologica, 92, 222–231.

    Article  PubMed  Google Scholar 

  19. Goldberg, J., Jacobsohn, D.A., Zahurak, M.L., and Vogelsang, G.B. (2005) Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol Blood Marrow Transplant, 11, 101–107.

    Article  PubMed  Google Scholar 

  20. Stiff, P.J., Emmanouilides, C., Bensinger, W.I., Gentile, T., Blazar, B., Shea, T.C., Lu, J., Isitt, J., Cesano, A., and Spielberger, R. (2006) Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol, 24, 5186–5193.

    Article  PubMed  CAS  Google Scholar 

  21. Spielberger, R., Stiff, P., Bensinger, W., Gentile, T., Weisdorf, D., Kewalramani, T., Shea, T., Yanovich, S., Hansen, K., Noga, S., McCarty, J., LeMaistre, C.F., Sung, E.C., Blazar, B.R., Elhardt, D., Chen, M.G., and Emmanouilides, C. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med, 351, 2590–2598.

    Article  PubMed  CAS  Google Scholar 

  22. Filipovich, A.H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J.R., Lee, S.J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., Cowen, E.W., Dinndorf, P., Farrell, A., Hartzman, R., Henslee-Downey, J., Jacobsohn, D., McDonald, G., Mittleman, B., Rizzo, J.D., Robinson, M., Schubert, M., Schultz, K., Shulman, H., Turner, M., Vogelsang, G., and Flowers, M.E. (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant, 11, 945–956.

    Google Scholar 

  23. Markey, K.A., MacDonald, K.P., and Hill, G.R. (2008) Impact of cytokine gene polymorphisms on graft-vs-host disease. Tissue Antigens, 72, 507–516.

    Article  PubMed  CAS  Google Scholar 

  24. Rocha, V., Franco, R.F., Porcher, R., Bittencourt, H., Silva, W.A. Jr., Latouche, A., Devergie, A., Esperou, H., Ribaud, P., Socie, G., Zago, M.A., and Gluckman, E. (2002) Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood, 100, 3908–3918.

    Article  PubMed  CAS  Google Scholar 

  25. Holler, E., Rogler, G., Brenmoehl, J., Hahn, J., Greinix, H., Dickinson, A.M., Socie, G., Wolff, D., Finke, J., Fischer, G., Jackson, G., Rocha, V., Hilgendorf, I., Eissner, G., Marienhagen, J., and Andreesen, R. (2008) The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. Int J Immunogenet, 35, 381–384.

    Article  PubMed  CAS  Google Scholar 

  26. Dickinson, A.M., Middleton, P.G., Rocha, V., Gluckman, E., and Holler, E. (2004) Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol, 127, 479–490.

    Article  PubMed  CAS  Google Scholar 

  27. Mayor, N.P., Shaw, B.E., Hughes, D.A., Maldonado-Torres, H., Madrigal, J.A., Keshav, S., and Marsh, S.G. (2007) Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol, 25, 4262–4269.

    Article  PubMed  CAS  Google Scholar 

  28. Elmaagacli, A.H., Koldehoff, M., Hindahl, H., Steckel, N.K., Trenschel, R., Peceny, R., Ottinger, H., Rath, P.M., Ross, R.S., Roggendorf, M., Grosse-Wilde, H., and Beelen, D.W. (2006) Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation, 81, 247–254.

    Article  PubMed  CAS  Google Scholar 

  29. Sioud, M. and Floisand, Y. (2009) NOD2/CARD15 on bone marrow CD34+ hematopoietic cells mediates induction of cytokines and cell differentiation. J Leukoc Biol, 85, 939–946.

    Article  PubMed  CAS  Google Scholar 

  30. Ferrara, J.L., Levine, J.E., Reddy, P., and Holler, E. (2009) Graft-versus-host disease. Lancet, 373, 1550–1561.

    Article  PubMed  CAS  Google Scholar 

  31. Graca, L., Thompson, S., Lin, C.Y., Adams, E., Cobbold, S.P., and Waldmann, H. (2002) Both CD4(+)CD25(+) and CD4(+)CD25(–) regulatory cells mediate dominant transplantation tolerance. J Immunol, 168, 5558–5565.

    PubMed  CAS  Google Scholar 

  32. Hara, M., Kingsley, C.I., Niimi, M., Read, S., Turvey, S.E., Bushell, A.R., Morris, P.J., Powrie, F., and Wood, K.J. (2001) IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol, 166, 3789–3796.

    PubMed  CAS  Google Scholar 

  33. Maul, J., Loddenkemper, C., Mundt, P., Berg, E., Giese, T., Stallmach, A., Zeitz, M., and Duchmann, R. (2005) Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology, 128, 1868–1878.

    Article  PubMed  CAS  Google Scholar 

  34. Rieger, K., Loddenkemper, C., Maul, J., Fietz, T., Wolff, D., Terpe, H., Steiner, B., Berg, E., Miehlke, S., Bornhauser, M., Schneider, T., Zeitz, M., Stein, H., Thiel, E., Duchmann, R., and Uharek, L. (2006) Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood, 107, 1717–1723.

    Article  PubMed  CAS  Google Scholar 

  35. Bolwell, B., Sobecks, R., Pohlman, B., Andresen, S., Rybicki, L., Kuczkowski, E., and Kalaycio, M. (2004) A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant, 34, 621–625.

    Article  PubMed  CAS  Google Scholar 

  36. Baron, F., Little, M.T., and Storb, R. (2005) Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev, 19, 153–164.

    Article  PubMed  Google Scholar 

  37. Cutler, C., Stevenson, K., Kim, H.T., Richardson, P., Ho, V.T., Linden, E., Revta, C., Ebert, R., Warren, D., Choi, S., Koreth, J., Armand, P., Alyea, E., Carter, S., Horowitz, M., Antin, J.H., and Soiffer, R. (2008) Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood, 112, 4425–4431.

    Article  PubMed  CAS  Google Scholar 

  38. Perfetti, P., Carlier, P., Strada, P., Gualandi, F., Occhini, D., Van Lint, M.T., Ibatici, A., Lamparelli, T., Bruno, B., Raiola, A.M., Dominietto, A., Di Grazia, C., Bregante, S., Zia, S., Ferrari, G.M., Stura, P., Pogliani, E., and Bacigalupo, A. (2008) Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant, 42, 609–617.

    Article  PubMed  CAS  Google Scholar 

  39. Apisarnthanarax, N., Donato, M., Korbling, M., Couriel, D., Gajewski, J., Giralt, S., Khouri, I., Hosing, C., Champlin, R., Duvic, M., and Anderlini, P. (2003) Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant, 31, 459–465.

    Article  PubMed  CAS  Google Scholar 

  40. Greinix, H.T., Knobler, R.M., Worel, N., Schneider, B., Schneeberger, A., Hoecker, P., Mitterbauer, M., Rabitsch, W., Schulenburg, A., and Kalhs, P. (2006) The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica, 91, 405–408.

    PubMed  Google Scholar 

  41. Couriel, D., Saliba, R., Hicks, K., Ippoliti, C., de Lima, M., Hosing, C., Khouri, I., Andersson, B., Gajewski, J., Donato, M., Anderlini, P., Kontoyiannis, D.P., Cohen, A., Martin, T., Giralt, S., and Champlin, R. (2004) Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood, 104, 649–654.

    Article  PubMed  CAS  Google Scholar 

  42. Van Lint, M.T., Milone, G., Leotta, S., Uderzo, C., Scime, R., Dallorso, S., Locasciulli, A., Guidi, S., Mordini, N., Sica, S., Cudillo, L., Fagioli, F., Selleri, C., Bruno, B., Arcese, W., and Bacigalupo, A. (2006) Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood, 107, 4177–4181.

    Article  PubMed  Google Scholar 

  43. Berger, M., Biasin, E., Saglio, F., and Fagioli, F. (2008) Innovative approaches to treat steroid-resistant or steroid refractory GVHD. Bone Marrow Transplant, 42(Suppl 2), S101–S105.

    Article  PubMed  CAS  Google Scholar 

  44. Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M.E., Remberger, M., Dini, G., Egeler, R.M., Bacigalupo, A., Fibbe, W., and Ringden, O. (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371, 1579–1586.

    Article  PubMed  Google Scholar 

  45. Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., and Marr, K. (2009) Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis, 48, 265–273.

    Article  PubMed  CAS  Google Scholar 

  46. Maertens, J., Meersseman, W., and Van Bleyenbergh, P. (2009) New therapies for fungal pneumonia. Curr Opin Infect Dis, 22, 183–190.

    Article  PubMed  CAS  Google Scholar 

  47. Hebart, H. and Einsele, H. (2004) Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol, 65, 432–436.

    Article  PubMed  CAS  Google Scholar 

  48. Haque, T., Wilkie, G.M., Taylor, C., Amlot, P.L., Murad, P., Iley, A., Dombagoda, D., Britton, K.M., Swerdlow, A.J., and Crawford, D.H. (2002) Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet, 360, 436–442.

    Article  PubMed  Google Scholar 

  49. Haque, T., Wilkie, G.M., Jones, M.M., Higgins, C.D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., Amlot, P.L., Kelly, D., MacGilchrist, A., Gandhi, M.K., Swerdlow, A.J., and Crawford, D.H. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 110, 1123–1131.

    Article  PubMed  CAS  Google Scholar 

  50. Mackinnon, S., Thomson, K., Verfuerth, S., Peggs, K., and Lowdell, M. (2008) Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis, 40, 63–67.

    Article  PubMed  CAS  Google Scholar 

  51. Einsele, H., Kapp, M., and Grigoleit, G.U. (2008) CMV-specific T cell therapy. Blood Cells Mol Dis, 40, 71–75.

    Article  PubMed  CAS  Google Scholar 

  52. Hogan, W.J. and Deeg, H.J. (2005) Stem cell transplantation: graft-mediated antileukemia effects. Methods Mol Med, 109, 421–444.

    PubMed  CAS  Google Scholar 

  53. Weiden, P.L., Flournoy, N., Thomas, E.D., Prentice, R., Fefer, A., Buckner, C.D., and Storb, R. (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med, 300, 1068–1073.

    Article  PubMed  CAS  Google Scholar 

  54. Weiden, P.L., Sullivan, K.M., Flournoy, N., Storb, R., and Thomas, E.D. (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med, 304, 1529–1533.

    Article  PubMed  CAS  Google Scholar 

  55. Ringden, O., Labopin, M., Gluckman, E., Reiffers, J., Vernant, J.P., Jouet, J.P., Harousseau, J.L., Fiere, D., Bacigalupo, A., Frassoni, F., and Gorin, N.C. (1997) Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Transplant Proc, 29, 733–734.

    Article  PubMed  CAS  Google Scholar 

  56. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C., Speck, B. et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555–562.

    PubMed  CAS  Google Scholar 

  57. Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., Mittermueller, J., de Witte, T., Holler, E., and Ansari, H. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041–2050.

    PubMed  CAS  Google Scholar 

  58. Bacigalupo, A., Soracco, M., Vassallo, F., Abate, M., Van Lint, M.T., Gualandi, F., Lamparelli, T., Occhini, D., Mordini, N., Bregante, S., Figari, O., Benvenuto, F., Sessarego, M., Fugazza, G., Carlier, P., and Valbonesi, M. (1997) Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant, 19, 927–932.

    Article  PubMed  CAS  Google Scholar 

  59. Guglielmi, C., Arcese, W., Dazzi, F., Brand, R., Bunjes, D., Verdonck, L.F., Schattenberg, A., Kolb, H.J., Ljungman, P., Devergie, A., Bacigalupo, A., Gomez, M., Michallet, M., Elmaagacli, A., Gratwohl, A., Apperley, J., and Niederwieser, D. (2002) Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood, 100, 397–405.

    Article  PubMed  CAS  Google Scholar 

  60. Soiffer, R.J., Alyea, E.P., Hochberg, E., Wu, C., Canning, C., Parikh, B., Zahrieh, D., Webb, I., Antin, J., and Ritz, J. (2002) Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant, 8, 625–632.

    Article  PubMed  Google Scholar 

  61. Baron, F., Siquet, J., Schaaf-Lafontaine, N., Baudoux, E., Hermanne, J.P., Fillet, G., and Beguin, Y. (2002) Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. Haematologica, 87, 78–88.

    PubMed  Google Scholar 

  62. Ciceri, F., Bonini, C., Gallo-Stampino, C., and Bordignon, C. (2005) Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy, 7, 144–149.

    Article  PubMed  CAS  Google Scholar 

  63. Stauss, H.J. (1999) Immunotherapy with CTLs restricted by nonself MHC. Immunol Today, 20, 180–183.

    Article  PubMed  CAS  Google Scholar 

  64. Bae, J., Martinson, J.A., and Klingemann, H.G. (2005) Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clin Cancer Res, 11, 1629–1638.

    Article  PubMed  CAS  Google Scholar 

  65. Moris, A., Teichgraber, V., Gauthier, L., Buhring, H.J., and Rammensee, H.G. (2001) Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J Immunol, 166, 4818–4821.

    PubMed  CAS  Google Scholar 

  66. Bae, J., Martinson, J.A., and Klingemann, H.G. (2004) Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia. Cell Immunol, 227, 38–50.

    Article  PubMed  CAS  Google Scholar 

  67. Amrolia, P.J., Reid, S.D., Gao, L., Schultheis, B., Dotti, G., Brenner, M.K., Melo, J.V., Goldman, J.M., and Stauss, H.J. (2003) Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood, 101, 1007–1014.

    Article  PubMed  CAS  Google Scholar 

  68. Gao, L., Yang, T.H., Tourdot, S., Sadovnikova, E., Hasserjian, R., and Stauss, H.J. (1999) Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. Blood, 94, 2999–3006.

    PubMed  CAS  Google Scholar 

  69. Heemskerk, M.H., Hoogeboom, M., de Paus, R.A., Kester, M.G., van der Hoorn, M.A., Goulmy, E., Willemze, R., and Falkenburg, J.H. (2003) Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood, 102, 3530–3540.

    Article  PubMed  CAS  Google Scholar 

  70. Ljunggren, H.G. and Karre, K. (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today, 11, 237–244.

    Article  PubMed  CAS  Google Scholar 

  71. Moretta, L., Ciccone, E., Moretta, A., Hoglund, P., Ohlen, C., and Karre, K. (1992) Allorecognition by NK cells: nonself or no self?. Immunol Today, 13, 300–306.

    Article  PubMed  CAS  Google Scholar 

  72. Ruggeri, L., Mancusi, A., Burchielli, E., Capanni, M., Carotti, A., Aloisi, T., Aversa, F., Martelli, M.F., and Velardi, A. (2008) NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis, 40, 84–90.

    Article  PubMed  CAS  Google Scholar 

  73. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F., and Velardi, A. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295, 2097–2100.

    Article  PubMed  CAS  Google Scholar 

  74. Dodero, A., Carniti, C., Raganato, A., Vendramin, A., Farina, L., Spina, F., Carlo-Stella, C., Di Terlizzi, S., Milanesi, M., Longoni, P., Gandola, L., Lombardo, C., and Corradini, P. (2009) Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood, 113, 4771–4779.

    Article  PubMed  CAS  Google Scholar 

  75. Schaffer, M., Malmberg, K.J., Ringden, O., Ljunggren, H.G., and Remberger, M. (2004) Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation, 78, 1081–1085.

    Article  PubMed  Google Scholar 

  76. Lee, G.K., Park, H.J., Macleod, M., Chandler, P., Munn, D.H., and Mellor, A.L. (2002) Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology, 107, 452–460.

    Article  PubMed  CAS  Google Scholar 

  77. Munn, D.H. and Mellor, A.L. (2004) IDO and tolerance to tumors. Trends Mol Med, 10, 15–18.

    Article  PubMed  CAS  Google Scholar 

  78. Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B., Brown, C., and Mellor, A.L. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 281, 1191–1193.

    Article  PubMed  CAS  Google Scholar 

  79. Mellor, A.L. and Munn, D.H. (2001) Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses. J Reprod Immunol, 52, 5–13.

    Article  PubMed  CAS  Google Scholar 

  80. Munn, D.H., Sharma, M.D., Hou, D., Baban, B., Lee, J.R., Antonia, S.J., Messina, J.L., Chandler, P., Koni, P.A., and Mellor, A.L. (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest, 114, 280–290.

    PubMed  CAS  Google Scholar 

  81. Munn, D.H. and Mellor, A.L. (2006) The tumor-draining lymph node as an immune-privileged site. Immunol Rev, 213(1), 146–158.

    Article  PubMed  Google Scholar 

  82. Jasperson, L.K., Bucher, C., Panoskaltsis-Mortari, A., Taylor, P.A., Mellor, A.L., Munn, D.H., and Blazar, B.R. (2008) Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood, 111, 3257–3265.

    Article  PubMed  CAS  Google Scholar 

  83. Steckel, N.K., Kuhn, U., Beelen, D.W., and Elmaagacli, A.H. (2003) Indoleamine 2,3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance? Scand J Immunol, 57, 185–191.

    Article  PubMed  CAS  Google Scholar 

  84. Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M.G., and Bordignon, C. (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 296, 2410–2413.

    Article  PubMed  CAS  Google Scholar 

  85. Aiuti, A., Brigida, I., Ferrua, F., Cappelli, B., Chiesa, R., Marktel, S., and Roncarolo, M.G. (2009) Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. Immunol Res, 44, 150–159.

    Article  PubMed  Google Scholar 

  86. Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., Tabucchi, A., Carlucci, F., Eibl, M., Aker, M., Slavin, S., Al-Mousa, H., Al Ghonaium, A., Ferster, A., Duppenthaler, A., Notarangelo, L., Wintergerst, U., Buckley, R.H., Bregni, M., Marktel, S., Valsecchi, M.G., Rossi, P., Ciceri, F., Miniero, R., Bordignon, C., and Roncarolo, M.G. (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med, 360, 447–458.

    Article  PubMed  CAS  Google Scholar 

  87. Santilli, G., Thornhill, S.I., Kinnon, C., and Thrasher, A.J. (2008) Gene therapy of inherited immunodeficiencies. Expert Opin Biol Ther, 8, 397–407.

    Article  PubMed  CAS  Google Scholar 

  88. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M.H., Pike-Overzet, K., Chatters, S.J., de Ridder, D., Gilmour, K.C., Adams, S., Thornhill, S.I., Parsley, K.L., Staal, F.J., Gale, R.E., Linch, D.C., Bayford, J., Brown, L., Quaye, M., Kinnon, C., Ancliff, P., Webb, D.K., Schmidt, M., von Kalle, C., Gaspar, H.B., and Thrasher, A.J. (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest, 118, 3143–3150.

    Article  PubMed  CAS  Google Scholar 

  89. Goldman, J.M. and Melo, J.V. (2003) Chronic myeloid leukemia – advances in biology and new approaches to treatment. N Engl J Med, 349, 1451–1464.

    Article  PubMed  CAS  Google Scholar 

  90. Martinez, N., Drescher, B., Riehle, H., Cullmann, C., Vornlocher, H.P., Ganser, A., Heil, G., Nordheim, A., Krauter, J., and Heidenreich, O. (2004) The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer, 4, 44.

    Article  PubMed  Google Scholar 

  91. Heidenreich, O., Krauter, J., Riehle, H., Hadwiger, P., John, M., Heil, G., Vornlocher, H.P., and Nordheim, A. (2003) AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood, 101, 3157–3163.

    Article  PubMed  CAS  Google Scholar 

  92. Scherr, M., Battmer, K., Winkler, T., Heidenreich, O., Ganser, A., and Eder, M. (2003) Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood, 101, 1566–1569.

    Article  PubMed  CAS  Google Scholar 

  93. Robbins, M.A., Li, M., Leung, I., Li, H., Boyer, D.V., Song, Y., Behlke, M.A., and Rossi, J.J. (2006) Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol, 24, 566–571.

    Article  PubMed  CAS  Google Scholar 

  94. Parham, P. (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol, 5, 201–214.

    Article  PubMed  CAS  Google Scholar 

  95. Ruggeri, L., Mancusi, A., Burchielli, E., Aversa, F., Martelli, M.F., and Velardi, A. (2007) Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol, 19, 142–147.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Rikshopitalet–Radiumhospitalet, University Hospital, Oslo, Norway

    Yngvar Fløisand

  2. Department of Immunology, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet, University Hospital, Oslo, Norway

    Mouldy Sioud

Authors
  1. Yngvar Fløisand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mouldy Sioud
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute for Cancer Research, Dept. Immunology, Norwegian Radium Hospital, Montebello, Oslo, 0310, Norway

    Mouldy Sioud

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Fløisand, Y., Sioud, M. (2010). Recent Advances in Hematopoietic Stem Cell Transplantation and Perspectives of RNAi Applications. In: Sioud, M. (eds) RNA Therapeutics. Methods in Molecular Biology, vol 629. Humana Press. https://doi.org/10.1007/978-1-60761-657-3_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-657-3_30

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-656-6

  • Online ISBN: 978-1-60761-657-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation